To study the efficacy and safety of rivaroxaban combined with catheter thrombolysis in the treatment of acute lower extremity deep venous thrombosis.

50 patients with acute lower extremity deep venous thrombosis were enrolled in our hospital from June 2015 to May 2017. 50 patients were divided into control group(treated with catheter thrombolysis, n=25)and observation group(treated with rivaroxaban and catheter thrombolysis, n=25). Statistical analysis were performed by using SPSS 22.0 software, Measurement data such as serum inflammatory factors, coagulation parameters and measurement of limb circumference before and after treatment were expressed as mean±standard deviation and examined by using t-test. The clinical efficacy, adverse reactions and recurrence were compared by using chi square test. A P value of <0.05 was considered as statistically significant difference.

The clinical efficacy of 96.00% in observation group was significantly higher than 72.00% in control group (χ²=5.36, P=0.02). After treatment, The serum levels of hs-CRP, IL-6 and TNF-α in observation group were significantly lower than those control group respectively (P<0.01). The coagulation index DD and FIB in observation group were significantly higher than those in control group respectively (P<0.01). The levels of PT and APTT were lower than those in control group respectively (P<0.05). The recurrence rate of observation group at 6 months after treatment was significantly lower than that in control group (χ²=5.71, P=0.02). In addition, there was no significant difference of adverse reaction rate between two groups (P>0.05).

Rivaroxaban combined with catheter thrombolysis in the treatment of acute lower extremity deep venous thrombosis has a definite curative effect. It could inhibit the inflammatory reaction and improve the coagulation function of patients with good prognosis and safety. It is worthy of clinical promotion.